Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,359.57% | 10.99% | 124.91% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,359.57% | 10.99% | 124.91% | -- | -- |
| Cost of Revenue | 15.32% | 34.10% | 16.12% | 27.37% | 284.96% |
| Gross Profit | -5.99% | -38.20% | -2.21% | 2.92% | -282.31% |
| SG&A Expenses | -34.72% | -6.66% | 8.95% | -42.66% | -22.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.97% | 15.86% | 13.00% | -23.63% | 39.12% |
| Operating Income | 12.22% | -16.30% | -5.35% | 31.86% | -38.59% |
| Income Before Tax | 15.93% | -18.08% | -6.47% | 35.84% | -41.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.93% | -18.08% | -6.47% | 35.84% | -41.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.93% | -18.08% | -6.47% | 35.84% | -41.00% |
| EBIT | 12.22% | -16.30% | -5.35% | 31.86% | -38.59% |
| EBITDA | 12.24% | -16.19% | -5.21% | 31.99% | -38.46% |
| EPS Basic | 47.25% | 25.75% | 33.08% | 50.17% | 0.03% |
| Normalized Basic EPS | 47.25% | 25.76% | 33.08% | 50.18% | 0.03% |
| EPS Diluted | 47.25% | 25.75% | 33.08% | 50.17% | 0.03% |
| Normalized Diluted EPS | 47.25% | 25.76% | 33.08% | 50.18% | 0.03% |
| Average Basic Shares Outstanding | 59.36% | 59.02% | 59.11% | 28.76% | 41.04% |
| Average Diluted Shares Outstanding | 59.36% | 59.02% | 59.11% | 28.76% | 41.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |